Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505934 | 1.00 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9721831 | 0.84 | TDP1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28903042 | 0.83 | CYP1A2 (0.42) | CA1CA2CA9 | |
| SCHEMBL4851435 | 0.83 | LMNA (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10794414 | 0.81 | ACACB (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28903050 | 0.81 | ALDH1A1 (0.48) | CA1CA2CA9MAOB | |
| SCHEMBL28903049 | 0.81 | ALDH1A1 (0.48) | CA1CA2CA9MAOB | |
| SCHEMBL9713465 | 0.81 | LTA4H (0.47) | LMNA | |
| SCHEMBL9713456 | 0.81 | LTA4H (0.47) | LMNA | |
| SCHEMBL10790174 | 0.78 | LMNA (0.36) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | GHSR, GHRHR, PRLHR | CA12 3287/4885CA1 4019/4885CA2 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.